with remain XXXX report continues again, Thank you, quarter, health everyone totaling revenue $XX a able to second be to morning, am to and everyone. good once hope I record million. safe. and I is Raj, quarter pleased,
up Second from second first increased of the quarter was sequentially X% XXX% and XXXX, quarter the revenue year. over quarter of this
a strong quarter updated of geographies that sales of focus momentum, strong first $XXX innovation Our with momentum million the Implants the our results previous and not gains. in million. over demand as years to and XX% to by based with on And in post in share our of XX we industry. resonate guidance we range expect excellent strong the accident to share are continued continue can results. share underlying to that $XXX guidance With story of million XXXX. with we for to XX% growth raising women's our outlook continues This our to drive remain a most a to an updated upward and guidance outcomes revision we a and clinical on is track million continued provided achieve strong track on including our represents over capturing surgeons, This $XXX Motiva It business, of our world. This aesthetic significant $XXX with results. from of full-year around dominant women, market to XXXX health, captures show record science, importantly position singular
share consideration to we countries thanks up as our continues unusual is pandemic are world. in over market confident and the the that more campaigns gains all seasonality business, volatility a over continue While will to pronounced create near-term some the quarter-to-quarter vaccination our open
moment. quarter outlook we to the of impact additional with in updated performance on take detail approach always, provide a COVID, and a especially will Renee guidance. conservative second to As continue will our and
and breast immune and inflammatory a biocompatible an also titled, been XX higher degrees that, Nature The significantly roughness of of cited initiatives. panel at completely samples. Hopkins, is Humans, has by published determining surfaces. in the Engineering. led capsules The scientific was researchers the be Johns to the optimal tissue her, surface Langer, the in looked an key as of researchers with update Mediates X,XXX in group joined reduces And in On The recent well a Mice, of that amount of the of several inflammation. one foreign least that implants events, on and Response Professor Breast Topography surface on to amount of and is highlight [Brunswick] of spot and Baylor markers inflammatory would in researchers turn College induces the The SmoothSilk surface animal Medicine, Anderson, the I compared implant The sweet was MD both from of on top Surface healthy of the most of co-founder engineers patented history. response University published, I showed to University, among Medical was Motiva He call articles. most human on or and response. and XXX,XXX, Rice a as a expression researchers paper to published capsule, that paper Rabbits University MIT, Manchester, tissue is at a Biomedical MIT, body smooth the Silicone the at Body [Ph]. distinguished of the by limiting than Robert by Before but over the focused paper consistently formed, inducing shown models MIT, and author more of on Professors SmoothSilk the Institute study provide the He were the of authored This and over cited, June and Implants like Moderna. Foreign XX, decorated was he
a the more is is evidence real-world hard more increasingly And others our a in to Motiva team designed by we are the review can surface excessive of say science the [a The Professor findings excellent hard complications. field. this for Biomedical Rica. with rigorous reduce in Langer with response. an medical accident designing competition. SmoothSilk which in And implants most the the and towards into The April and who that its device sets the and positive and their enhancement surface Dr. over of implants inflammation sales to approved importance behind invasive this Motiva surgeons surgeons and terms about paper that Costa the seen study, ignore. step superior them, XX, technology we He Motiva in announced, and well-recognized change this the Mia us said all a As in determining more paper our journal patient women is consistently body it biocompatible clinical breast apart the significant strong respected It implants that optimal data by minimally On add Langer's the was them. purposefully is the The is safer went community XXX-patient consistently on use to minimizing procedure, foreign is our adding from completion to overstate. Engineering resonating the outcomes. [Ph]. Motiva and links to spans] journals a over process. show to world. by more our patients Nature message And work not and of that of decade From inception are show study demanding body Mia, ago results of in Nature their of outcomes IRB
this will to breast belief perform cases our continue that We approach transform aesthetics. that reaffirm
addressable used reminder, different not technology a women enhancement market. will Mia total supports to the regions surgeons Motiva had positive potential have our As has many breast appealing breast aesthetics. who who make from The the to view previously Mia from our that considered feedback expand
tissue several a XXXX. important an breast a a in non-magnetic, expander, Flora paradigm and expander clinical reminder, commercial the reconstruction port, many And the strategy The is Flora an the allows their outcomes a to estimate MRI with standard studies has alternatives to treated imaging Europe recon, come and And also how part first projects which Regulatory opportunity move potential improve help of cancer breast are underway call As a part the mission. reconstruction oncology safer, than a part than its new the for meaningfully Motiva but are this after of being Flora, Flora for of sales. initial women opens million journey cancer. health not from offering for women's clinical aesthetic by breast a less global in mastectomy. planned begun launch current to state larger have goal total new radiation patients. can during the system non-magnetic countries real X.X create allow per to that XX% way time we the year, what used to has of this better during By after tools in reconstruction for the to we clearance a breast should for have in critical a is the is on improve our Mia similar number provide up long-term Mia is total aesthetic of higher. one our around make addressable novel With remains also Motiva our world market there Flora to define planning. Flora kind track, for treatment is only benefits In outcomes woman's recovery. changing of market. a limited women procedures for that is mastectomy.
upon builds Ergonomix rollout select several mechanical flagship ErgonomixX Our in geographies. implant, our offers The and ErgonomixX advanced enhanced platform properties, continues improved ergonomics. chemistry, and
a in which will satisfaction result we premium. of patient believe greater even All price and justify
efforts to Our we commercial process. China in and progress continue clinical ongoing, regulatory the and or in make
in is market this Motiva to plan in Our launch XXXX.
remain cohort the for Our U.S. the timelines regulatory two-year year, of aesthetic In unchanged. pass mark. this approval August will also
a the enroll to revision fully reconstruction cohort reconstruction continue patients have reminder, the And cohort. in we trial. remaining as the completed of We
announced Corporate continue been Pratip our as invaluable Lastly, in of Amazon, Toprani already ServiceMaster, from we contributions insights He's at short will She Secretary. joined Operations. Biomet, our I came here. Zimmer Counsel June, have highlight base. as to that as time several initiatives. significant Pratip's at the be to transformation and and joined that In and the and expand as experience to been processes additions Neeta business others and transforming Global tell In I team announced to digital her such General she's us Salesforce, HP, you our revenue that also can we overseeing Establishment Dastidar May, in scaling companies recent want we Labs. Head
and industry, as strategy our market. plastic we very well our She Reconstructive Surgery U.S. Plastic their Brennan of community. to U.S. We the the Manager years, us where joins MTF, of most the hire also Head past June, our She Operations. as for from she worked and of General into Heather prepare in among announced, in surgeon the planning recently deep the Heather is Commercial respected division. is already as XX enter
month, with Of this as Gaeta's Establishment last in She is California. opportunity another Labs. to home we leaving course, earnings announced pursue earlier call is this her closer to Renee us
my call him passion with results. working health few over our Head our continued focusing He his industry now CFO. cover women's appreciate We Renee will our enjoyed us, understanding from interim make have natural Raj and a shares Investor wellness. to financial our on our Jefferies. Relations by I our experience to turn transform and as and important of support Denhoy, Strategy company. taking business, the in and role appointed choice And months, a Raj the February, deep and on to in him this past of current to joined growth. him has I background he have
